分子标志物预测晚期乳腺癌新辅助化疗疗效的研究  

Study of Molecular Markers to Predict the Effect of Neoadjuvant Chemotherapy on Advanced-Stage Breast Cancer

作　　者：艾秀清[1] 贾志莺[2] 张银华[3] 木妮热·木沙江[1] 

机构地区：[1]新疆医科大学附属肿瘤医院乳腺放疗科,新疆乌鲁木齐830011 [2]新疆医科大学附属肿瘤医院超声科,新疆乌鲁木齐830011 [3]新疆医科大学附属肿瘤医院病理科,新疆乌鲁木齐830011

出　　处：《医学临床研究》2016年第2期212-215,共4页Journal of Clinical Research

基　　金：新疆维吾尔自治区自然科学基金（2014211C114）

摘　　要：【目的】探讨分子标志物Survivin、HER-2、p53对预测晚期乳腺癌新辅助化疗疗效的意义。【方法】选取2014年1月至2015年1月本院接受新辅助化疗的晚期乳腺癌患者120例作为研究对象，通过免疫组织化学方法对瘤体组织化疗前后分子标志物Survivin、HER2、p53进行检测，通过统计学分析化疗前后各因子表达变化及其与各因子间的相关性。【结果】化疗前后各因子表达因疗效区别不存在差异（P〉0.05），Survivin、HER-2的阳性表达在化疗后明显低于化疗前（P〈0.05），而p53的阳性表达变化在化疗前后并无差异（P〉0.05），化疗前Survivin与HER-2表达呈正相关，与p53表达无相关性，化疗后Survivin与HER-2、p53均呈正相关。【结论】Survivin、HER-2、p53在化疗前可能不具有预测新辅助化疗治疗晚期乳腺癌的效果，但可作为评价化疗疗效的指标。【Objective】To investigate the effects of Survivin, HER2, and p53 to predict the effect of neoadjuvant chemotherapy on advancedstage breast cancer. 【Methods】The 120 patients with advancedstage breast cancer and who had received neoadjuvant chemotherapy in our hospital from 2013 January to 2015 January were recruited as subjects. The expression changes and its relations to each factor were analyzed before and after chemotherapy. 【Results】 There were no differences in each factors expression before and after chemotherapy. The positive expression of Survivin and HER2 after chemotherapy were significantly lower than those of before chemotherapy （P〈0.05）, but the difference in p53 was not statistically significant（P〉0.05）. The Survivin and HER2 before chemotherapy showed positive correlation to each other but not to p53 before chemotherapy; the Survivin and HER2 showed positive correlation after chemotherapy. 【Conclusion】Survivin ,HER2, and p53 can not predict the effect of neoadjuvant chemotherapy on advancedstage breast cancer, but they can be the targets for evaluating the chemotherapy effect.

关 键 词：抑制蛋白 受体 erbtY2 肿瘤抑制蛋白质P53 乳腺肿瘤/药物疗法 

分 类 号：R737.9[医药卫生—肿瘤]